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1. Introduction 
This chapter highlights current state-of-the-art methods for the detection and identification 
of Mycobacterium tuberculosis (Mtb) complex in the clinical diagnostic laboratory. Methods 
discussed include stain and culture which traditionally would have been followed by 
phenotypic-based identification methods. At this point in time however, molecular methods 
are considered the gold standard for both the rapid detection of Mtb directly from patient 
specimens as well as for the identification of Mtb following growth in culture. There are also 
instances where speciation of Mtb in order to distinguish it from other members of the Mtb 
complex is clinically important and these will be discussed. In addition, this chapter 
provides an overview of methods used in the clinical laboratory for Mtb drug resistance 
testing and suggests what the future might hold for Mtb diagnostics.  
2. M. tuberculosis and biosafety in the clinical laboratory 
M. tuberculosis presents a risk of laboratory-acquired infection due to its transmission via 
aerosol routes, ability to withstand common laboratory processing techniques such as heat-
fixation or frozen section preparation and a extremely low ID50 of <10 bacilli. The United 
States Centers for Disease Control and Prevention (CDC) estimates that laboratory workers 
are three times more likely than non-laboratory workers to become infected with Mtb. 
Therefore, biological safety organizations have defined a number of safety practices and 
procedures that must be strictly followed when working with Mtb which is classified as a 
risk group 3 organism. Specimens and cultures of unknown isolates shall be handled as if 
they contain Mtb until proven otherwise. Only non-aerosol generating processes such as 
accessioning of specimen or reading of acid-fast smears can be done under BSL-2 conditions 
outside of a BSC. All other specimen-handling including opening/closing of tubes, pipeting 
and transfer must be done in a BSC. Personnel must exercise caution to avoid aerosol 
generation. More specifically, smear preparation, culture decontamination and 
concentration, and culture plating must be done inside a BSC with the possible exception of 
the centrifugation step. However, centrifugation must be done using aerosol-proof 
containers which are opened, loaded and closed inside the BSC to reduce the risk of 
personnel exposure. All laboratory surfaces must be decontaminated with a tuberculocidal 
reagent before and after working with specimens and cultures. Propagation and 
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manipulation of Mtb complex cultures (e.g., identification and susceptibility testing) 
requires BSL-3 practices, equipment and facilities. Clinical laboratories without BSL-3 
facilities must refer all positive mycobacterial cultures to another laboratory with BSL-3 
capabilities for identification and, if necessary, susceptibility testing. Acid-fast smears must 
not be prepared from positive mycobacterial cultures of unknown identity without BSL-3 
facilities. Identification methods (e.g., biochemical analysis, nucleic acid hybridization 
probes, sequencing, PCR) required initial specimen processing under BSL-3 conditions until 
any viable mycobacteria have been rendered non-viable by heating and/or lysis via 
chemical or physical means. Laboratories must verify that their processing methods are 
effective in rendering Mtb nonviable prior to conducting any activities outside of a BSL-3 
laboratory. 
BSL-3 facilities have highly specialized requirements some of which include restricted 
laboratory access, self-closing double door entry, directional airflow with a specified 
number of air exchanges over time, BSCs exhausted to the outside, and posted signage 
regarding the hazard (in this case Mtb). Class II BSCs are one of the most important pieces of 
equipment in the mycobacteriology laboratory and they must be maintained in good 
working order at all times. Frequent (at least daily) checks of function by means such as 
magnehelic gauge monitoring is needed. Regular maintenance and certification programs 
must be undertaken and documentation of cabinet performance must be maintained by the 
laboratory. Specimens should be covered before transport and should be transported in 
well-sealed, leak-proof containers. All biohazard waste should be autoclaved prior to 
leaving the facility.  
BSL-3 personnel safety practices include the use of fluid-resistant, cuffed, solid-front 
gowns, gloves, eye protection, respiratory protection (N-95 or better fitted respirator or 
powered air purifying respirator (PAPR)). Each laboratory must perform a risk 
assessment to define the personal protective equipment, facilities and engineering 
practices that are appropriate for their institution and that comply with applicable 
regulations. The risk assessment is the responsibility of the laboratory director but it 
should be done in collaboration with institutional biosafety officials as this is helpful in 
making certain that no safety practice has been overlooked. A sample risk assessment is 
provided in Table 1 but each laboratory must perform their own assessment as situations 
may differ between laboratories. The laboratory must have a written spill procedure and 
must review the procedure with lab staff regularly to assure competency. Spill “drills” in 
which staff physically respond to a simulated spill are highly recommended as they 
routinely point out any potential gaps in procedures or staff knowledge. 
Strict regulations exist in many countries concerning the shipping and transportation of 
diagnostic specimens that are known to contain or that potentially contain Mtb complex and 
for shipment of known Mtb complex isolates. Personnel who package these specimens and 
isolates must have specialized training that is updated at prescribed intervals. Packaging 
materials must be leak-proof, able to withstand unpredictable handling throughout the 
transportation chain and must be properly labeled in order to alert transportation workers 
of hazards contained within the package. Individuals involved in the shipping of specimens 
and isolates should be knowledgeable about the regulations within their country and if, 
sending specimens or isolates internationally, within the destination country.  
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Procedure 
Aerosol 
Potential 
Biosafety 
Level 
Required 
Personal 
Protective 
Equipment 
Required 
Engineering 
Controls 
Required 
Special Practices or 
Equipment Required 
Reading of 
smears (AR, 
Kinyoun, 
Modified Acid 
Fast) 
Slight BSL 2 Gown, gloves 
May be done on 
bench top 
 
Manipulation 
of 
mycobacterial 
cultures for 
identification 
(e.g. 
subculturing) 
Significant BSL 3 
Gown, shoe 
covers, eye 
protection,  
gloves and 
respirator/head 
cover or PAPR 
Work in biological 
safety cabinet 
Use disposable loops; 
Use racks to prevent 
tipping/spilling; 
Work over 
disinfectant-soaked 
towel 
Susceptibility 
testing of 
mycobacteria 
Significant
BSL 3 for 
setup 
BSL 2 for 
incubation 
and 
reading of 
closed 
bottles/ 
plates/ 
tubes 
Setup - Gown, 
shoe covers, eye 
protection, gloves 
and 
respirator/head 
cover or PAPR 
Work in biological 
safety cabinet to 
inoculate bottles, 
tubes or plates 
with organism 
Use extreme care to 
avoid aerosol 
generation when 
inoculating 
bottles/plates/tubes 
Table 1. Sample partial risk assessment – this table is intended as an example of one style of 
risk assessment that can be developed. Each laboratory must develop a laboratory-specific 
risk assessment in conjunction with their institutional safety officer(s). 
3. Stains for mycobacteria 
Mycobacteria, including Mtb complex, can be rapidly and inexpensively detected directly 
from pretreated and concentrated respiratory specimens, body fluids, and tissue using 
acid-fast stains. A Gram stain is not able to reliably detect mycobacteria which can appear 
as non-stained “ghosts” or as beaded Gram-positive bacilli. Therefore, acid-fast stains, 
such as the Ziehl-Neelsen stain or the fluorescent auramine-rhodamine stain are 
recommended for mycobacteria. The acid-fast stain forms a complex between the unique 
mycolic acids of the mycobacterial cell wall and the dye (e.g., fuchsin). Complex 
formation makes the mycobacteria resistant to destaining by acid-alcohols providing the 
basis for the “acid-fast” terminology. Non-acid fast bacteria do not retain the acid-fast dye 
in the presence of the acid-alcohol decolorizer and are often stained in a subsequent step 
using a counterstain such as methylene blue. Commonly utilized acid-fast stains contain 
carbol-fuchsin dye and are the Ziehl-Neelsen stain which utilizes phenol plus heat to aid 
in dye penetration, and the Kinyoun stain which uses phenol in the absence of heat. The 
Ziehl-Neelsen stain is considered the more sensitive of the two (Somoskovi et al., 2001). 
Fluorescent stains such as auramine O are also used alone or in combination with 
rhodamine B. The fluorescent stains exhibit increased fluorescence upon binding DNA 
and RNA providing enhanced sensitivity for examining concentrated direct specimens by 
www.intechopen.com
 
Understanding Tuberculosis – Global Experiences and Innovative Approaches to the Diagnosis 
 
6 
staining the bacilli while avoiding non-specific staining of artifacts and background more 
typical of the non-fluorescent stains. 
Mycobacteria appear as long slender rods (1-10µm long x 0.2-0.6µm wide) and are often 
slightly curved or bent. At least 300 fields should be examined under high power (1000X) 
when using a carbol-fuchsin stain and light microcopy. The fluorochrome stain can be 
examined using a lower power (250X) and a minimum of 30 fields should be examined 
under the lower power (Pfyffer & Palicova, 2011). When positive, an indication of the 
quantity of acid-fast bacilli present should be provided. Factors which influence the 
sensitivity of acid-fast smears include the amount of acid-fast bacilli present in the 
specimen, the experience of the reader, the stain used, the number of fields examined, the 
type of specimen (e.g., generally respiratory specimens have higher yield than non-
respiratory), the patient population being examined, volume of the specimen and smear pre-
treatment (direct vs. pre-treated, concentrated). Rigid quality control processes must be 
followed to prevent cross-contamination and false results. Laboratories should use a 
positive and negative control slide for each batch of acid-fast smears prepared and should 
have a second reader confirm positive results and at least 10% of negative slides to reduce 
the potential for incorrect results. Staining jars or dishes should not be used to prevent 
potential cross-contamination and care should be taken to avoid the transfer of bacilli via the 
microscopy oil used for examining the slide. Laboratories must also participate in a 
proficiency testing programs (e.g., College of American Pathologists) to ensure continued 
competency. 
Acid-fast stains lack sensitivity and a large number of bacilli (104-106/mL) are required for a 
positive stain. Therefore, a positive stain from a respiratory specimen is typically thought to 
correlate with a higher infectivity potential and patients are routinely placed in airborne 
isolation rooms until their acid-fast smears convert to negative. Immunocompromised 
individuals often present with lower bacterial loads making detection by smear difficult 
(Chegou et al., 2011). Up to 30% of persons (commonly children) are unable to produce 
sputum for a smear requiring the use of more invasive methods (gastric washing, 
bronchoalveolar lavage, etc). Smears can be used to follow the response to treatment in 
smear-positive individuals. A concentration step provides increase sensitivity over direct 
smear microscopy (Steingart et al., 2006). 
Acid-fast stains are also non-specific and the reader cannot determine the species of 
mycobacteria present in a positive smear. Mycobacteria tend to clump and produce cord-
like strands of bacilli and there may be some indication of which species is present based on 
characteristic cording but this is highly subjective and not recommended as a routine 
method of determining species (Attorri et al., 2000; Julian et al., 2010).  
4. Culturing of M. tuberculosis 
The growth of Mtb in culture is considered the gold standard for identification of a case of 
tuberculosis. The sensitivity of culture is much better than an acid-fast smear with only 10-
100 viable organisms/mL of specimen required for a positive culture. Media for the growth 
of Mtb is the same as that used for other mycobacteria species and generally includes both a 
solid and a liquid-based medium. Solid media utilized is typically either egg-based such as 
the Lowenstein-Jensen (L-J) medium or agar-based such as Middlebrook 7H10 medium. 
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Antimicrobial agents can be added to help with elimination of contaminating organisms 
which may have a more rapid growth rate than Mtb and which may therefore obscure any 
Mtb present on the plate. In general, Mtb colonies are seen more rapidly on agar-based 
medium (10-12 days) as opposed to egg-based medium (18-24 days) (Liu et al., 1973). Care 
must be taken to protect Middlebrook medium from excessive light and heat which results 
in breakdown of the medium and release of a formaldehyde byproduct which is toxic to Mtb 
(Miliner et al., 1969). Use of Middlebrook 7H11 medium containing casein is reported to 
improve the recovery of isoniazid-resistant isolates of Mtb (Pfyffer & Palicova, 2011). Broth 
medium such as Middlebrook 7H9 medium is reported to provide a more rapid recovery of 
Mtb compared with solid medium. There are several commercially-available semi-
automated broth culture systems for mycobacteria including Mtb complex. The BACTEC 
460 radiometric and BACTEC 960 Mycobacterial Growth Indicator Tube (MGIT) 
fluorimetric systems (Becton, Dickinson, Sparks, MD) and the VersaTREK culture system 
(TREK Diagnostics Systems, Cleveland, OH) are FDA-cleared in the United States. The 
BACTEC 460 system is currently being phased out by the manufacturer in favor of the non-
radiometric MGIT system. Other culture systems include Septi-Chek biphasic System 
(Becton, Dickinson,) and the MB/BacT Alert 3D system (bioMérieux, Marcy l'Etoile, France) 
which has a colorimetric CO2-based sensor to detect mycobacterial growth. There are 
numerous publications in the literature which compare the performance of the 
commercially-available broth systems but in general, these systems have a sensitivity of 88-
93% for the detection of Mtb complex (Cruciani et al., 2004).  
Cultures for Mtb complex should be incubated at 35-37ºC in an atmosphere of 5-10% CO2 for 
primary cultures on solid medium. Since Mtb complex grows slowly in culture, many 
laboratories choose to examine culture plates for growth twice per week during early stages 
of growth and then weekly for older cultures. The advantage of semi-automated broth 
systems such as the MGIT and VersaTREK are that CO2-supplementation is not generally 
required and the cultures are continuously monitored without the need for laboratory 
technologist intervention unless a culture is flagged by the instrument as positive. After 
either a solid or broth culture shows growth, the presence of acid-fast bacilli must be 
confirmed as described below in order to rule out non-mycobacterial contaminants. 
5. Identification of M. tuberculosis from culture isolates 
5.1 Microscopy 
The first step in the examination of organisms growing on either solid media or liquid 
media is to confirm their identity using various staining methods as discussed in section 3. 
Depending on the stain used, the identification of Mycobacterium bacilli is done using either 
a light microscope under 100 x oil immersion objective or a fluorescent microscope under 
25x or 40x objective. Microscopy however is not specific and cannot differentiate Mtb from 
other Mycobacterium and further analysis is required for final identification which can take 
up to 4-6 weeks.  
Recently, the Microscopic Observation Drug Susceptibility (MODS) assay has been reported 
for the detection of Mtb complex in liquid culture through microscopic observation of 
characteristic cording and this method is characterized as in “late stage 
development/evaluation” for use in high TB burden settings by the World Health 
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Organization (WHO) (Caviedes & Moore, 2007; Moore, 2007; WHO, 2008; Ha et al., 2009; 
Limaye et al., 2010). 
5.2 Biochemical analysis 
Following microscopic and microscopic examination of culture isolates, final identification 
to the species level of Mtb complex is performed using a set of conventional biochemical 
reactions in combination with growth temperature. Although conventional biochemical 
assays are relatively inexpensive and simple to perform, they are time-consuming due to 
required incubation periods of up to 4 weeks, resulting in major delays in identification. 
Furthermore, with greater than 130 mycobacterial species identified to date, the use of 
phenotypic methods is limited and biased to identify only the most common species of 
mycobacteria, underestimating the complexity of the genus and resulting in 
misidentification of unfamiliar species (Kirschner et al., 1993; Springer et al., 1996). M. 
tuberculosis, as with other members of the Mtb complex, is a slow growing mycobacterium, 
requiring in general 15 days to 40 days to grow in culture. The optimal isolation 
temperature for the organism is 35-37°C and the organism does not produce pigmentation 
even following exposure to light (non-chromogen). The most useful biochemical tests used 
for identification of a nonchromogenic, slow-growing mycobacterium such as Mtb complex 
includes: niacin accumulation, nitrate reduction, pyrazinamidase activity, inhibition of 
thiophene-2-caroxylic acid hydrazide, urease activity and catalase activity. Other tests that 
can provide additional information include tellurite reduction, Tween 80 hydrolysis, the 
arylsulfatase test, iron uptake and NaCl tolerance. In general, a mature growth (2-3 weeks) 
is required for biochemical tests, they are often performed on a LJ slants and require up to 3 
weeks for final read of results. 
5.2.1 Niacin accumulation 
Niacin (nicotinic acid) is produced by all species of mycobacteria and further metabolized to 
nicotinamide adenine dinucleotide (NAD). However, Mtb complex, M. simiae and some 
strains of M. chelonae, M. bovis, and M. marinum do not have the enzyme responsible for 
metabolizing niacin, resulting in its accumulation in the culture media. A water extract is 
prepared by adding 1 mL of sterile water to the surface of an LJ slant with a growth of 
mycobacteria species at least three weeks-old. An aliquot of this extract is then added to a 
tube containing a niacin strip, incubated for up to 30 minutes with gentle shaking. A 
positive reaction (presence of niacin) is read as the development of a yellow color. Since 
species other than Mtb complex can accumulate niacin, additional biochemical testing is 
required for the final identification of Mtb complex.  
5.2.2 Nitrate reduction 
M. tuberculosis complex contains the enzyme nitroreductase which is able to reduce nitrate 
(NO3) into nitrite (NO2). This reaction is detected in the laboratory by inoculating a nitrate 
broth with a loopful of a 3-4 weeks old mycobacterial culture and ┙-napthalamine, and 
sulfanilic acid that will react with the released NO2 to produce a red or pink color. A 
negative result (lack of color) is further confirmed by the addition of zinc dust. If a red color 
(nitrate reduced) develops following addition of zinc dust, then the original result is 
confirmed as negative. 
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5.2.3 Pyrazinamidase 
The deamination of pyrazinamide into pyrazinoic acid and ammonia by the enzyme 
pyrazinamidase (PZA) is an essential test to distinguish Mtb complex (PZA positive) from 
M. bovis (PZA negative). Other non-tuberculous mycobacteria species including M. 
marinum and M. avium complex can also be positive for PZA. The test is performed by 
inoculating two LJ slants with the mycobacterium species and incubating them for 4 days 
at 35-37°C in a non-CO2 incubator. After 4 days, 1% ferric ammonium sulphate is added to 
one of the tube and incubated at room temperature for 30 minutes. The PZA reaction is 
positive if a pink band forms on the surface of the LJ slant. If the reaction is negative, the 
LJ slant is incubated for an additional 4 hours at 2-8 °C and observed for the appearance 
of the pink band. If the test is still negative after 4 hours, the second tube will be tested on 
day 7 to finalize the test.  
5.2.4 Urease 
The presence of urease, the enzyme that hydrolyzes urea into ammonia and carbon dioxide, 
can be detected in mycobacterial species by incubating an actively growing culture to a urea 
broth for up to 7 days at 35-37°C in a non-CO2 incubator, with readings done at days 1, 3 
and 7. M. tuberculosis complex is positive for urease and will produce a dark pink to red 
color following incubation in urea broth.  
5.2.5 Inhibition of thiophene-2-caroxylic acid hydrazide (TCH) 
M. tuberculosis complex can be differentiated from M. bovis by its ability to grow in the 
presence of TCH, a property shared by most mycobacteria species except for M. bovis. This 
test uses quadrant Petri dishes with one of the quadrant containing TCH. A dilute 
suspension of the mycobacterial growth (10-3 to 10-4 in sterile water) is added to each 
quadrant and the plate incubated for 3 weeks at 35-37°C in a 10 % CO2 incubator. A resistant 
organism shows greater than 1% growth in the TCH quadrant when compared to growth in 
the control quadrant.  
5.2.6 Arylsulfatase test 
Arylsulfatase is an enzyme that hydrolyzes free phenolphthalein from the tri-potassium salt 
of phenolphthalein disulfite. A suspension of a pure mycobacterium culture in sterile water 
is incubated with phenolphthalein in oleic acid agar for either 3 days (rapid growers) or 14 
days (slow growers) at 35-37°C in a non-CO2 incubator. The appearance of a pink or red 
color after addition of sodium bicarbonate (Na2CO3) indicates a positive reaction. All 
members of the Mtb complex lack the arylsulfatase enzyme and are therefore negative for 
that reaction (Koneman, 2006; Lee, 2010). 
5.2.7 Catalase test 
Catalase is an enzyme that splits hydrogen peroxide (H2O2) into water (H2O) and oxygen 
(O2). Unlike the catalase assay used to identify for other types of bacteria (i.e. Streptococcus 
spp.), the catalase assay for mycobacteria is performed using 30% H2O2 (Superoxol) in 10% 
Tween-80 and the test performed both at 22-25°C and 68°C. M. tuberculosis complex has 
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catalase activity at 22-25°C but not at 68°C (ie., heat-labile catalase). In addition to 
determining catalase activity at 68°C, the strength of the catalase reaction is also evaluated 
to differentiate Mtb complex from other mycobacteria. This semiquantitative test is 
performed by adding Superoxol to a 2-weeks-old culture of mycobacteria growing on a 
Lowenstein-Jensen slant at 37°C. Five minutes after addition of the Superoxol, the strength 
of the catalase reaction is determined by measuring the height of the bubbles, characteristic 
of the catalase reaction, in the tube. If the height of the bubbles is > 45 mm, the reaction is 
considered high and if the height of the bubbles is < 45 mm, the reaction is considered low. 
M. tuberculosis complex has low catalase activity.  
5.2.8 Iron uptake 
Only a few mycobacteria species are able to take up iron from ferric ammonium citrate and 
convert it to iron oxide (rust). This biochemical reaction is mainly used to identify M. 
fortuitum which when incubated with 20% ferric ammonium citrate for up to 3 weeks on a 
Lowenstein-Jensen slant at 28-30°C will turn a dark, rusty brown color. M. tuberculosis 
complex does not take up iron. 
5.2.9 NaCl tolerance 
The ability to grow on media containing 5% NaCl differentiates the slow growing 
mycobacteria from the rapid growers as only M. triviale (a slow grower) can grow on this 
media and only M. chelonae and M. mucogenicum (rapid growers) fails to grow in the 
presence of this salt concentration. The test is performed by inoculating an LJ slant 
containing 5% NaCl with a 1 MacFarland concentration of a mycobacterial culture and 
incubating it at 28°C in a 5-10% CO2 incubator for up to 4 weeks (Witebsky & Kruczak-
Filipov, 1996; Lee, 2010). M. tuberculosis complex does not grow on LJ slant containing 5% 
NaCl.  
5.2.10 Tellurite reduction 
Most mycobacterium can reduce potassium tellurite to metallic tellurium in liquid broth 
within 3 days. The test is performed by inoculating a Middlebrook 7H9 liquid medium 
containing Tween 80 with a heavy concentration of organisms and incubating at 37°C in a 5-
10% CO2 incubator for up to 7 days. After 7 days, a solution of potassium tellurite is added 
to the liquid culture and further incubated for 3 days. A positive reaction shows a black 
precipitate (metallic tellurium) at the bottom of the tube. This test is often used to identify 
MAC. M. tuberculosis complex is negative for tellurite reduction (Witebsky & Kruczak-
Filipov, 1996; Lee, 2010).  
5.2.11 Tween 80 hydrolysis 
This assay tests for the presence of the enzyme lipase which can cleave the oleic acid from 
the detergent Tween 80 (polyoxyethylene sorbitan monooleate). The release of the oleic acid 
from Tween 80 results in a change of color of the neutral indicator from yellow to red within 
5-10 days after incubation of Tween-80 with a mycobacterium at 37°C in a 5-10% CO2 
incubator. M. tuberculosis complex is negative for Tween 80 hydrolysis.  
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The use of conventional methods for the initial identification of Mtb complex is not ideal. 
This section provided a review of the most common tests used traditionally but the 
combined use of these various assays results in a significant delay in identification of up to 
one month after growth of the culture in the laboratory. The following sections will cover 
the more rapid methods currently in use in most mycobacteriology laboratory for 
identification of Mtb complex.  
 
Biochemical Test Reaction 
niacin accumulation Positive 
nitrate reduction Positive 
pyrazinamidase activity Positive 
urease activity Positive 
inhibition of thiophene-2-caroxylic acid hydrazide (TCH) Positive 
arylsulfatase test Negative 
catalase test Negative (heat-labile) 
iron uptake Negative 
NaCl tolerance Negative 
tellurite reduction Negative 
Tween 80 hydrolysis Negative 
Table 2. Biochemical tests for identification of Mycobacterium tuberculosis complex from a 
culture isolate 
5.3 High-Performance Liquid Chromatography 
High-performance liquid chromatography (HPLC) of mycolic acids was first proposed for 
use as a standard test in mycobacteria species identification by the CDC in 1985. This 
technique had been widely used by clinical chemistry laboratories for the separation and 
identification of drug compounds (Butler & Guthertz, 2001). HPLC can be used to 
differentiate mycobacteria based on differences in their mycolic acid profiles. Mycolic acids 
are high-molecular weight fatty acids with long carbon side chains present in abundance in 
the cell wall of mycobacteria and other organisms including Corynebacterium, Dietzia, 
Rhodococcus, Nocardia, Gordonia, Williamsia, Skermania, and Tsukamurella species with 
Mycobacterium species containing the longest carbon chain (60-90) (Butler & Guthertz, 2001). 
Mycolic acids samples are prepared through a series of steps involving saponification of the 
mycobacteria, organic solvent extraction and derivatization of the mycolic acids to UV-
adsorbing p-bromophenacyl (PBPA) esters (Durst et al., 1975; Butler et al., 1991). The 
derivatized mycolic acids solution is then separated on a HPLC instrument and the resulting 
chromatogram interpreted based on the peak pattern which is specific for each species of 
mycobacterium (Butler et al., 1991; Butler & Guthertz, 2001).  
Although sensitive and specific when compared to biochemical tests and other molecular 
assays, with agreement ranging from 90-99% depending on the mycobacterial species 
(Guthertz et al., 1993; Thibert & Lapierre, 1993), HPLC is a technically demanding method 
which is not easily implemented in routine diagnostic laboratories. This method requires a 
high level of expertise for recognition of species based on the HPLC chromatogram and 
therefore only limited to a few reference laboratories including the CDC in Atlanta, GA. A 
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commercial HPLC assay, the Sherlock Mycobacteria Identification HPLC system (SMIS; 
MIDI Inc., Newark, DE), was developed to simplify use of HPLC in the clinical laboratories 
through automated recognition of mycobacterial species based on software that analyzes 
HPLC peak patterns comparing them to a library containing several Mycobacterium species 
chromatograms (Kellogg et al., 2001; LaBombardi et al., 2006). Of the 370 isolates tested in a 
multicenter study by SMIS, 327 (88%) were identified to the species level by the SMIS 
software with 279 (75%) correctly identified (Kellogg et al., 2001). The sensitivity of the SMIS 
identification could be increased to 98.9% (366/370) by manual calculation of relative peak 
height ratios and relative retention times and additional biochemical properties. In another 
study by LaBombardi et al. (LaBombardi et al., 2006), the SIMS correctly identified 61/90 
isolates (67.8%) growing on Middlebrook 7H11 plates (BBL, Sparks, MD) and 73/161 
(45.3%) isolates growing in VersaTREK Myco bottles (TREK Diagnostic Systems, Cleveland, 
OH). This performance was increased by used of a modified library to 91% for isolates 
growing on solid media and 83.2% for isolates recovered from liquid culture. In both 
studies, no Mtb complex isolates were misidentified and the sensitivity ranged from 83-
100% (Kellogg et al., 2001; LaBombardi et al., 2006). Of note, although HPLC is a faster and 
more sensitive technology than conventional biochemical testing, this method cannot be 
used directly on clinical specimen and is not able to differentiate between members of the 
Mtb complex, except for the M. bovis BCG strain (Butler et al., 1991; Floyd et al., 1992).  
5.4 Nucleic acid hybridization probes  
The introduction of nucleic acid hybridization probes in the clinical laboratory significantly 
impacted the turn-around time and workload for identification of mycobacteria species. 
Nucleic acid hybridization probes are single-stranded or double-stranded DNA/RNA 
fragments, labeled with a radioactive, chemiluminescent or a fluorescent marker, that are 
complementary to a target DNA or RNA sequence (Wetmur, 1991). In clinical microbiology, 
nucleic acid hybridization probes often target ribosomal RNA (rRNA) because of their high 
copy number present in organisms growing in culture. The first nucleic acid hybridization 
probes from Gen-Probe (San Diego, CA) for rapid identification of M. avium complex and 
Mtb complex were labeled with I125 radioactive isotope. Labeled DNA-RNA complexes were 
separated from non-hybridized DNA using an adsorption suspension containing 
hydroxyapatite and the I125 in the adsorbed labeled complex was counted using a gamma 
counter. Results were calculated as percentage of input probe hybridized (Drake et al., 1987; 
Kiehn & Edwards, 1987; Ellner et al., 1988; Musial et al., 1988; Peterson et al., 1989). The 
introduction of these radioactive probes resulted in a significant decrease in the turn-around 
time for identification of both M. avium complex and Mtb complex from weeks to 
approximately 2 hours with sensitivity and specificity ranging from 83-100% and 99.2-100% 
respectively (Drake et al., 1987; Kiehn & Edwards, 1987; Ellner et al., 1988; Musial et al., 
1988; Peterson et al., 1989).  
The I125 probes were eventually replaced with non-radioactive probes to reduce staff 
potential for exposure to radioactive materials. Two types of non-isotopic probes were 
introduced, the synthetic nucleic acid probes (SNAP) (Syngene, Inc., San Diego, CA) and the 
AccuProbes (Gen-Probe, San Diego, CA). The SNAP probes utilized DNA probes labeled 
with alkaline-phosphatase and was performed by spotting the isolate to be tested on a nylon 
membrane and incubating the membrane with the labeled probes, followed by incubation in 
www.intechopen.com
 
Clinical Laboratory Diagnostics for Mycobacterium tuberculosis 
 
13 
a solution of nitroblue tetrazolium chloride, 5-brom-4-chloro-3- indolyphosphate substrates 
and alkaline phosphatase buffer. A positive reaction was read as the presence of a blue or 
purple color on the nylon membrane within a few hours (Lim et al., 1991; Woodley et al., 
1992). Although 100% sensitive, cross-reactivity was detected with SNAP probes between 
Mtb complex and M. terrae, requiring the 68°C catalase test to be performed to differentiate 
between the two species (Lim et al., 1991; Ford et al., 1993).  
AccuProbes are labeled with acridinium ester and hybridization is measured by 
chemiluminescence following hydrolysis of the label upon addition of H2O2 and NaOH. The 
chemiluminescence is measured using a luminometer and expressed as RLU (relative light 
units). Unlike the previous version with the I125 isotope, no wash steps are necessary as non-
hybridized probes are chemically degraded and only acridinium ester-labeled, hybridized 
probes can produce measurable chemiluminescence (Goto et al., 1991). The AccuProbe for 
Mtb complex can be performed on culture growing from both liquid and solid media and 
will detect all members of the Mtb complex (Gen-Probe, 2011). The sensitivity and specificity 
of the acridinium ester labeled probes was comparable to that of the radioisotope labeled 
probes (Goto et al., 1991; Lebrun et al., 1992). Similar to the SNAP probes, detection of some 
strain of M. terrae by Mtb complex probes was also observed (Lim et al., 1991; Ford et al., 
1993), although increased stringency in the detection method resolved the false-positive 
detection of M. terrae by AccuProbes Mtb complex probes. 
Although the use of nucleic acid probes has allowed same day identification of Mtb complex 
from culture, the sensitivity of these probes is not high enough for detection of the 
organisms directly from clinical specimens, which still limits the rapid identification to the 
time it takes for the organisms to grow in either liquid or solid media. Furthermore, the Mtb 
complex AccuProbes do not distinguish amongst members of the Mtb complex. 
5.5 Line Probe assays 
Line Probe assays were developed to expand the range of mycobacterium species identified 
using nucleic acid probes since those were only available for Mtb complex, M. avium, M. 
intracellulare, M. kansasii and M. gordonae (Gen-Probe, San Diego, CA). The first 
commercially available LineProbe assay, the INNO LiPa Mycobacteria (Innogenetics, Ghent, 
Belgium), uses reverse hybridization technology in which probes are immobilized as 
parallel lines on a membrane strips as opposed to being in solution as is the case with 
AccuProbes. Amplified, biotinylated DNA fragments of the 16-23S rRNA spacer region of 
mycobacterial organisms are incubated with the labeled strips; addition of streptavidin-
alkaline phosphatase and a chromogenic substrates results in the formation of a precipitate 
on the membrane where hybridization as occurred (Scarparo et al., 2001; Tortoli et al., 2001). 
The LiPa assay is able to detect up to 14 different species of mycobacteria (Table 3) and 
results are interpreted according to a flowchart decision scheme (Tortoli et al., 2001). A 
multicenter evaluation of LiPa assay conducted in Italy tested 238 mycobacterial organisms 
from both solid and liquid media as well as two Nocardia strains (Tortoli et al., 2001). All 
238 mycobacterial strains reacted with the genus specific probes for a sensitivity of 100% 
and 61 of the 238 strains were identified to the species level. The other 177 strains were 
outside of the detection range of the LiPa assay. Additional studies using only liquid culture 
media, MB/BacT Alert 3D (Organon Teknika, Boxtel, The Netherlands), and BACTEC 12B 
Bottles (BACTEC; Becton Dickinson, Sparks, MD), showed similar sensitivity of 100% for 
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detection of mycobacterial strains by the genus specific probes as well as correct 
identification at the species levels and specificity of 100% (Miller et al., 2000; Scarparo et al., 
2001). 
The LiPa test is a more complex assay than the AccuProbe, requiring highly skilled 
technologists and has a turn-around time of at least 6 hours, including a PCR amplification 
step. Furthermore, control of the hybridization temperature is key to preventing formation 
of non-specific bands. However, in addition to its ability to detect several mycobacterial 
species compared to AccuProbes, the Inno-LiPa assay has the advantage of being able to 
detect mixed mycobacterial infections which often results in decreased sensitivity of the 
AccuProbes (Scarparo et al., 2001). Both assays still have to be performed from organisms 
growing in culture and are not able to differentiate among the members of the Mtb complex. 
Another line probe assay, the GenoType Mycobacterium (Hain, Nehren, Germany) was 
developed and made available in two different kit formats. One kit, the Genotype 
Mycobacterium CM (Common Mycobacteria) was designed to detect the most frequently 
isolated mycobacteria species in clinical laboratories while the other kit, the Genotype 
Mycobacterium AS (Additional Species), was designed for the detection of less frequently 
encountered mycobacteria species (Makinen et al., 2006; Richter et al., 2006; Russo et al., 
2006). Russo and colleagues tested 197 isolates including genera other than mycobacteria 
previously identified by conventional biochemical tests, HPLC, Inno-Lipa and 16S rRNA 
sequencing (Russo et al., 2006). The sensitivity of the assay for the mycobacterium genus 
was 98.9 and 99.4% for the CM and AS kits respectively with a specificity of 100% for the AS 
kit and 88.9% for the CM kit due to weak cross-reaction of several strains of the genus 
Tsukamurella. The overall sensitivity and specificity for species identification was 97.9% and 
92.4% for the CM kit and 99.3% and 99.4% for the AS kit with all members of the Mtb 
complex correctly identified as Mtb complex by the CM kit and Mtb species by the AS kit. 
Similar performance were established in other independent studies evaluating the 
GenoType CM and AS kits, with the sensitivity and specificity for Mtb complex members 
approaching 100% when compared to 16S rRNA sequencing and biochemical testing 
(Makinen et al., 2006; Richter et al., 2006). 
A third kit from Hain LifeScience, the Genotype MTBC DNA strip assay was designed 
specifically for the differentiation of members of the Mtb complex and identification of M. 
bovis BCG. Similar to the LiPa assay, the MTBC DNA strip assay uses reverse hybridization 
technology on a solid membrane matrix. The DNA probes immobilized on the membranes 
target polymorphisms in the gyrB DNA sequence of the Mtb complex and the RD1 deletion 
of M. bovis BCG (Richter et al., 2003). Ritcher and colleagues (Richter et al., 2003) evaluated 
the performance of the MTBC assay using well-characterized strains of Mtb complex 
including Mtb, M. bovis subsp. bovis, M. bovis subsp. caprae, M. bovis BCG, M. africanum 
subtype I , M. africanum subtype II , M. canetti, and M. microti as well as clinical isolates of 
Mtb complex identified by conventional methods and other molecular tests (PCR-Restriction 
fragment length polymorphism). The MTBC assay was able to differentiate all species of the 
Mtb complex except for separating Mtb from some strains of M. africanum subtype II and M. 
canetti (sensitivity of 94%). A similar study conducted by Neonakis and colleagues showed 
100% agreement between conventional methods/AccuProbes and MTBC assay for the 
identification and differentiation of 120 clinical isolates of the Mtb complex (Neonakis et al., 
2007).  
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Species AccuProbes Inno-LiPa 
GenoType
CM 
GenoType 
AS 
GenoType 
MTBC 
Mycobacterium spp.  X X   
M. tuberculosis 
 complex 
X X X   
M. tuberculosis     X 
M. bovis subsp.  
bovis 
    X 
M. bovis BCG     X 
M. bovis subsp.  
caprae 
    X 
M. africanum     X 
M. microti     X 
M. kansasii X X X X  
M. avium X X X   
M. intracellulare X X X   
MAI-X  X    
M. malmonense  X X   
M. haemophilum  X  X  
M. scrofulaceum  X X   
M. paratuberculosis  X    
M. silvaticum  X    
M. chelonae  X X   
M. gastri  X  X  
M. xenopi  X X   
M. gordonae X X X   
M. abscessus   X   
M. fortuitum   X   
M. marinum   X   
M. ulcerans   X X  
M. peregrinum   X   
M. simiae    X  
M. mucogenicum    X  
M. goodii    X  
M. celatum    X  
M. smegmatis    X  
M. genavense    X  
M. lentiflavum    X  
M. heckeshornense    X  
M. szulgai    X  
M. phlei    X  
M. asiaticum    X  
M. shimoidei    X  
Table 3. Mycobacterium species detected by commercially available probe assays 
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5.6 DNA sequencing 
The first report of nucleic acid sequencing for the identification of mycobacteria appeared in 
the literature in the early 1990s. Rogall et al. (Rogall et al., 1990) described the use of a 1 kb 
gene fragment targeting the 5’ region of the 16S rRNA to detect and differentiate among the 
various species of mycobacteria, including the Mtb complex. In this study, amplified 
sequences were electrophoresed on a 6% sequencing gel, dried and the gel was exposed to 
X-rays film for 12 hours. Sequences obtained were then analyzed using a multisequence 
alignment algorithm from SAGE program (Rogall et al., 1990). This entire process was 
completed in approximately 2 days. Other nucleic acid targets were analyzed including the 
rpoB gene, encoding the ┚-subunit of the RNA polymerase, which had the added advantage 
of detecting rifampin resistance (Kim et al., 1999; Kasai et al., 2000), the 16-23S rDNA 
internal transcribed spacer (ITS) (Roth et al., 1998), the 32-kDa protein (Soini et al., 1994) and 
the 65 kDa heat shock protein (Kapur et al., 1995). Each of these targets presented 
advantages and disadvantages, mainly related to their ability to differentiate closely-related 
organisms. Today, sequencing of the 16S rDNA has become the gold standard for 
mycobacteria species identification. The process was eventually automated and 
commercialized (MicroSeq 500bp and 1500bp 16S rDNA Bacterial Sequencing Kits, Applied 
Biosystems, Carlsbad, CA), which resulted in standardization of the assay across 
laboratories. The MicroSeq 16S rDNA bacterial identification assay analyzes a larger portion 
of the 16S rDNA than the one described earlier by Rogall et al. (Rogall et al., 1990), resulting 
in increased discriminating power. The introduction of capillary electrophoresis and 
fluorescent dyes to replace the cumbersome sequencing gels and radioactive labels, the 
development of genetic analyzer and the National Center for Biotechnology Information 
(NCBI) tool, BLAST (Basic Local Alignment Sequence Tool), further improved on the use of 
sequencing for mycobacterial species identification.  
DNA sequencing using the MicroSeq system is based on sequencing by capillary 
electrophoresis and consists of 4 steps: DNA extraction, amplification, sequencing and data 
analysis. Total genomic DNA extraction is performed simply by lysis of organisms in a 
chaotropic solution (PrepMan Ultra, Applied Biosystems), followed by heating at 95°C for 
10 minutes to kill the organisms. Extraction is followed by 16S rRNA amplification, PCR 
products clean-up and sequencing PCR and analysis on a genetic analyzer. The sequence 
obtained is then analyzed against the MicroSeq database library and/or the BLAST database 
on the NCBI website (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
Studies evaluating the performance of the MicroSeq systems for identification of 
mycobacteria have repeatedly shown the advantages of using this technique over traditional 
biochemical tests and with the increase in available and correct sequences in various 
database, the sensitivity of the assay continues to increase (Patel et al., 2000; Cloud et al., 
2002; Hall et al., 2003; Woo et al., 2011). The main limitation of sequencing for identification 
of mycobacteria as discussed above remains the inability to distinguish several species of 
mycobacteria based solely on the 16S rRNA including M. chelonae, M. abscessus, and M. 
immunogenum and the various members of the Mtb complex (Hall et al., 2003; Woo et al., 
2011). Alternative sequencing targets (eg., rpoB) can often be used to distinguish 
mycobacterial species which cannot be resolved using the 16S target. 
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5.7 PCR methods (conventional and real-time) 
The pattern of resistance of pyrazinamide (PZA) is often used to distinguish between Mtb 
and M. bovis/M. bovis BCG strains (section 5.2.3). Only a few laboratory-developed tests 
(LDTs) have been designed to differentiate among members of the Mtb complex (Parsons et 
al., 2002; Huard et al., 2003; Pinsky & Banaei, 2008). Pinsky and Banaei (Pinsky & Banaei, 
2008) reported a real-time PCR assay, using a series of different primer pairs targeting the 
RD (region of difference) 9 (present in all Mtb complex members), the RD1 (absent in M. 
bovis BCG strains), the RD4 (absent in M. bovis). This multiplex real-time PCR uses melt 
curve analysis from two separate PCRs to identify and distinguish between Mtb, M. bovis, 
and M. bovis BCG directly from isolates growing in culture. Similarly, although on a 
conventional PCR format, the RD1 sequence was used as a target for the differentiation of 
Mtb, M. bovis, and M. bovis BCG from culture isolates (Lee et al., 2010). 
5.8 Immunoassay methods 
There are several commercially-available immunoassay methods which allow the 
identification of Mtb complex from culture by detection of Mtb-specific antigens. These tests 
are rapid requiring only minutes to perform after growth of the organism but literature 
reports indicate variable performance (Martin et al., 2011; Said et al., 2011; Steingart et al., 
2011; Yu et al., 2011) 
6. Direct identification of M. tuberculosis from clinical specimens 
6.1 Line probe assays 
The INNO LiPa Mycobacteria (Innogenetics), described previously in section 5.5, has been 
evaluated for use directly on clinical specimens without waiting for growth of Mtb complex 
in culture. In a study by Perandin et al. (Perandin et al., 2006), the INNO Lipa Mycobacteria 
assay was evaluated, with slight modifications, on both pulmonary specimens and 
extrapulmonary specimens (stools, urines, lymph nodes, gastric fluids and pus). The overall 
sensitivity and specificity of the test was 79.5% and 84.6% respectively for pulmonary 
specimens and 71.4% and 100 %, respectively for extrapulmonary specimens. As expected 
the sensitivity and specificity of the assay was much lower when tested on specimens than 
culture isolates and the authors suggested this was due to the lower numbers of organisms 
present in specimens.  
The INNO-LiPA Rif TB (Innogenetics) test, designed to detect Mtb complex and rifampin 
susceptibility in culture isolates, has also been tested on clinical specimens in multiple 
studies (Gamboa et al., 1998; de Oliveira et al., 2003; Johansen et al., 2003; Traore et al., 2006). 
In one of the largest studies, Traore and colleagues (Traore et al., 2006) evaluated the 
performance of the INNO-LiPA assay by testing 420 sputum samples from both treated and 
untreated patients, with 311 smear positive and 109 smear negative specimens. The assay 
detected Mtb complex DNA in 92% of smear positive specimens and 94.5% of smear 
negative specimens, a higher detection rate than culture which detected Mtb complex in 
74.3% of all specimens.  
An alternative version to the line assay GenoType Mycobacterium (Hain LifeScience), the 
GenoType Mycobacterium Direct Assay (Hain Lifescience) was designed to detect Mtb 
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complex and M. avium, M. intracellulare, M. kansasii, and M. malmoense directly from clinical 
specimens. This assay is performed in three parts consisting of an RNA isolation and 
capture step, followed by an isothermal amplification of the 23S rRNA, and finally a reverse-
hybridization of the amplified products on the membrane strips. Evaluation of this assay 
showed sensitivity and specificity ranging from 80.5-97% to 75-100% respectively when 
compared to culture (Franco-Alvarez de Luna et al., 2006; Seagar et al., 2008; Neonakis et al., 
2009; Kiraz et al., 2010). 
In general, the sensitivity of these line assays is lower when tested directly on clinical 
specimens as compared to their sensitivity when used on culture isolates. However, with a 
turn-around time of about 2 days compared to at least 6 weeks to obtain growth in culture, 
these assays, with their high specificity, provide information that is directly useful for 
clinical management of patients.  
6.2 FDA-approved PCR methods 
The first FDA-approved amplification test for diagnosis of Mtb complex was the Amplified 
Mycobacterium Tuberculosis Direct (MTD) test (Gen-Probe Inc, San Diego, CA). This assay 
was based on the amplification of Mtb complex rRNA followed by detection of the amplified 
rRNA by hybridization of chemiluminescent acridinium ester-labeled DNA probes. The 
sensitivity and specificity of the assay in earlier studies testing against N-acetyl-L-cysteine 
treated respiratory samples (smear positive and smear negative), was 91.9-100% and 97.6-
100%, respectively when compared to culture (Abe et al., 1993; Pfyffer et al., 1994; Welch et 
al., 1995). The MTD test presented several advantages over traditional methods including 
the use of rRNA, which is present in several copies in Mtb complex, rapid turn-around time 
(day vs. weeks), single tube amplification and detection, although culture is still required for 
susceptibility testing of the organisms (Abe et al., 1993; Pfyffer et al., 1994). The MTD test is 
only FDA-approved for respiratory specimens; however, the assay performance in 
extrapulmonary specimens has also been evaluated by several investigators. Vlaspodler et 
al. (Vlaspolder et al., 1995) showed variable sensitivity for different specimens with 
detection in pleural fluids being as low as 20% (with specificity of 96%) and sensitivity and 
specificity in other specimens, including urines, lymph nodes, CSF, gastric fluids and lung 
biopsies, of 100% and 95% respectively. Similar results were obtained in other studies that 
included a greater numbers of non-respiratory specimens, with sensitivities ranging from 
93-100% and specificities of 100% for both smear-positive and smear negative specimens 
(Chedore & Jamieson, 1999; Woods et al., 2001).  
A second PCR assay approved by the FDA was the AMPLICOR Mycobacterium tuberculosis 
test (AMPLICOR MTB; Roche Diagnostic Systems, Somerville, N.J.). This assay targeted the 
16S rRNA gene with colorimetric detection using probe hybridization (Piersimoni & 
Scarparo, 2003). In a study by D’Amato and colleagues, the sensitivity and specificity of the 
Amplicor MTB when compared to culture as the gold standard was: 55.3% and 99.6% from 
smear negative and 94.1% and 100% from smear positive respiratory specimens (D'Amato et 
al., 1995). Other studies showed sensitivity and specificity for the assay ranging from 70.4% 
to 79.5% with specificity greater than 98% when compared to culture and conventional 
microscopy (Schirm et al., 1995; Bergmann & Woods, 1996; Devallois et al., 1996) and 
sensitivity generally increasing 75-98 % for AFB positive specimens (Schirm et al., 1995; 
Bergmann & Woods, 1996). Testing of non-respiratory samples by the Amplicor MTB assay 
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supported its use in diagnosis of extrapulmonary tuberculosis as the sensitivity and 
specificity varied from 76%-100% and 99.9-100%, respectively when compared to clinical 
diagnosis (Shah et al., 1998). These non-respiratory specimens included various tissue 
biopsies (lung, lymph nodes, liver) and various body fluids (pleural, ascites, CSF, synovial, 
gastric, pericardial and peritoneal). 
A second version of the Amplicor assay, the Cobas Amplicor MTB-PCR (Roche Diagnostics) 
was developed as a semi-automated assay that combined the amplification, detection and 
reporting of results (Bodmer et al., 1997; Levidiotou et al., 2003). Evaluation of the new assay 
showed increased sensitivity over the manual assay with one study testing >1,000 
respiratory specimens reporting a sensitivity and specificity of 91.3% and 99.6% (Bodmer et 
al., 1997) and the other reporting an overall sensitivity and specificity of 82.5% and 99.8% 
after testing greater than 7,000 specimens (respiratory and non-respiratory)(Levidiotou et 
al., 2003). 
Both the MTD and the Amplicor assays were evaluated on broth samples including 
BACTECT 12B bottles (Becton Dickinson, Sparks, MD) and the ESP II (Trek Diagnostics, 
Westlake, OH), with sensitivity of greater than 90% for both assays in both media and 
specificity of 100% (Hernandez et al., 1997; Smith et al., 1997; Bergmann & Woods, 1999; 
Desmond & Loretz, 2001). 
6.3 Laboratory-developed PCR methods 
Several targets, including the 65-kD antigen of Mtb complex (Pao et al., 1990; Brisson-Noel et 
al., 1991; Totsch et al., 1994), the protein antigen B (Sjobring et al., 1990), the repetitive 
sequences IS6110 (Brisson-Noel et al., 1991; Eisenach et al., 1991; Sankar et al., 2010) and 
IS986 (Abe et al., 1993), have been used over the years for the detection of Mtb complex by 
LDTs. Earlier tests were based on conventional PCR, with a multi-step manual extraction 
process followed by amplification and detection of the amplified target on polyacrylamide 
gel. Depending on the target used, the sensitivity and specificity of these conventional PCR 
assays directly from respiratory specimens ranged from 84.2-100% and 62.6-100% with 
culture and clinical diagnosis used as a gold standard. However, due to limitations inherent 
with conventional PCR including high potential for cross-contamination, real-time PCRs, 
combined with automated extraction, have largely replaced these methods in clinical 
laboratories.  
Real-time PCR is faster than conventional PCR and does not require post-amplification 
manipulation of the amplified DNA, reducing the potential for cross-contamination. Several 
real-time PCR LDTs have been developed for diagnosis of pulmonary tuberculosis. In one of 
the earlier studies by Miller et al (Miller et al., 2002), a real-time PCR assay was developed 
on the LightCycler platform (Roche Diagnostics, Indianapolis, IN) with primers targeting 
the internal transcribed spacer region of the mycobacterium genome with specific 
hybridization probes designed for the detection of Mtb complex. The sensitivity and 
specificity of this assay for smear-positive respiratory specimens was 98.1% and 100% 
respectively with a turn-around time of less than 5 hours (Miller et al., 2002). Other studies, 
with different targets, have reported similar results (Shrestha et al., 2003) and many have 
been designed as multiplex assays to differentiate Mtb complex from other non-tuberculosis 
mycobacteria based on melting curve analysis (Shrestha et al., 2003). Furthermore, these 
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assays were often shown to be as sensitive and specific as the available commercial assays 
such as the Cobas Amplicor (Miller et al., 2002; Shrestha et al., 2003).  
Both conventional and real-time PCRs have also been developed for the diagnosis of 
extrapulmonary tuberculosis using both fresh specimens and paraffin-embedded tissues. 
Some of the fresh specimens that have been evaluated by various PCR include fine needle 
aspirates and tissue biopsies of lymph nodes, blood, urines, bone marrow aspirates and skin 
biopsies with variable sensitivities and specificities (Hsiao et al., 2003; Bruijnesteijn Van 
Coppenraet et al., 2004; Chakravorty & Tyagi, 2005; Ritis et al., 2005; Torrea et al., 2005; 
Rebollo et al., 2006). Although paraffin-embedded tissues are not optimal samples for PCR, 
often, they are the only specimens available to rule out tuberculosis. The sensitivity and 
specificity of PCR assays, conventional and real-time, on paraffin-embedded tissues varies 
from 64-100% and 73- 100%, respectively (Beqaj et al., 2007; Baba et al., 2008; Nopvichai et 
al., 2009; Luo et al., 2010). 
Unlike PCR assays previously mentioned for differentiation of members of Mtb complex, a 
real-time PCR assay, developed by Halse and colleagues (Halse et al., 2011) at the New York 
State Public Health Laboratory, showed the ability to differentiate among members of the 
Mtb complex directly from clinical specimens based on the detection of five targets 
including RD1, RD4, RD9, RD12 and a region external to RD9. The assay was able to detect 
155 of 165 clinical specimens (94%) and 708/727 (97%) of positive BACTEC MGIT-960 
bottles. Furthermore, this assay was able to distinguish not only Mtb, M. bovis and M. bovis 
BCG but also M. africanum, M. microti, and M. canettii. 
7. Drug resistance testing for M. tuberculosis 
The CDC published recommendations that drug susceptibility testing be performed on the 
first Mtb complex isolate from a each patient and also if a patient is failing therapy (based on 
clinical evidence or positive culture after three months on therapy) (MMWR, 1993). This 
recommendation was formulated following a resurgence in cases of tuberculosis from the 
mid-1980s to the early 1990s of up to 18% with resistance strains present in as high as 33% of 
cases in New York city (MMWR, 1993). Susceptibility testing is currently performed most 
commonly by traditional methods either agar-based or broth based methods with resistance 
defined as growth of greater than 1% of organisms tested against a specific drug (Canetti et 
al., 1963). 
7.1 Indirect proportion method 
Although patient specimens can be tested directly for drug susceptibility with the 
advantage of decreased time to results, this method is limited to smear-positive specimens 
and results may be difficult to interpret if contamination occurs (Woods, 2011). The 1% 
indirect proportion method is performed on Middlebrook 7H10 agar medium poured in a 
four-quadrant Petri dish with one quadrant serving as the control quadrant and containing 
no drug and the other three quadrants containing increasing concentration of the drug being 
tested. The inoculum is prepared using organisms growing on solid or liquid media 
adjusted to a 1.0 McFarland and diluted to 10-2 and 10-4; 0. 1 mL of each dilution is then 
added to each quadrant of separate plate and incubated for up to three weeks at 37 ± 1ºC in 
an atmosphere of 5 to 10% CO2 (CLSI, 2003). The percentage of drug resistance is calculated 
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by dividing the total colony count in a quadrant containing drug by the total colony count in 
the control quadrant (at least 50 colonies) and multiplying by 100. If the percentage is 
greater than 1%, then the organism is resistant and therapy with the drug tested is likely to 
fail (CLSI, 2008; Woods, 2011). This method is used primarily for susceptibility testing of the 
first line drugs, isoniazid (INH), rifampin (RIF) and ethambutol (EMB), as well as second 
line drugs, when resistance to RIF or two of the first-line drug is detected (CLSI, 2008). 
7.2 Rapid broth methods 
In order to circumvent the long turn-around time of the agar proportion methods and 
provide clinicians with timely drug susceptibility results, rapid broth methods were 
developed for both growth and susceptibility testing of Mtb complex. The first system, the 
BACTEC 460, was a based on measurement of radioactive 14CO2 produced by metabolic 
breakdown of 14C-labelled palmitic acid contained in a 7H12 liquid medium in the presence 
or absence of specific drugs (Middlebrook et al., 1977; Siddiqi et al., 1981; Snider et al., 1981; 
Laszlo et al., 1983). The agreement between the conventional and the radiometric 
susceptibility testing assays varied from 96.4-98% with most results obtained within 7 days 
(Siddiqi et al., 1981; Laszlo et al., 1983). Additionally, unlike the 1% indirect agar method, 
the radiometric method was conducive to testing of Mtb complex susceptibility against 
pyrazinamide (PZA), which requires an acidic environment not easily achievable on solid 
media. Heifets and Isman modified the radiometric method by lowering the pH with 
addition of phosphoric acid at the same time as PZA but after the growing culture had 
reached exponential phase (Heifets & Iseman, 1985). This initial study, with limited number 
of isolates, showed good correlation between PZA susceptibility as measured by the 
radiometric method and detection of the pyrazinamidase enzyme as described under 
biochemical testing (Heifets & Iseman, 1985). The method described by Heifets and Isman 
was further modified and proved useful in facilitating the measurement of PZA 
susceptibility of Mtb complex by the radiometric method (Tarrand et al., 1986; Salfinger & 
Heifets, 1988). 
The BACTEC 460 radiometric method for susceptibility testing was eventually replaced 
with the fully automated Mycobacteria Growth Indicator tube (MGIT 960, Becton Dickinson, 
Sparks, MD), which had been introduced for broth culture of mycobacteria species from 
clinical specimens without the use of radioactive materials (Chew et al., 1998; Heifets et al., 
2000). Each drug-containing MGIT bottle is inoculated with either 0.5 mL of a 1:100 dilution 
of a MGIT tube positive for 1-2 days, a 1:5 dilution of a MGIT tube positive for 3-5 days or a 
0.5 McFarland if the inoculum is prepared from an organism growing on solid media 
(Siddiqi, 2010). The control, drug-free MGIT bottle is inoculated with a 1:100 dilution of the 
inoculum used for the drug-containing MGIT bottle. The MGIT 960 system automatically 
interprets the results of the test based on the growth unit (GU). If the GU is greater than 100 
for a drug-containing MGIT bottle, the isolate is resistant and if the GU is less than or equal 
to 100 then the isolate is susceptible. However, for the test to be valid, the GU of the control 
bottle cannot reach 400 before 4 days or after 13 days, which suggests that the growth was 
too heavy or too light respectively (Woods, 2011). The MGIT 960 system is FDA-approved 
for susceptibility testing of Mtb complex against the first-line drugs including RIF (2 µg/ml), 
INH (0.4 µg/ml and 0.1 µg/ml), and EMB (7.5 µg/ml and 2.5 µg/ml), PYZ (100 µg/ml) and 
streptomycin (STR, 6.0 µg/ml and 2.0 µg/ml) (CLSI, 2008). Evaluation of the MGIT 
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performance for the primary tuberculosis drugs showed results that were comparable to the 
BACTEC 460 radiometric methods as well as the agar proportion methods (>90% 
agreement) (Ardito et al., 2001; Adjers-Koskela & Katila, 2003; Scarparo et al., 2004), except 
for EMB and STR which had agreement varying from less than 80% to 98% (Adjers-Koskela 
& Katila, 2003; Scarparo et al., 2004; Hall et al., 2006; Garrigo et al., 2007). More recently, the 
MGIT 960 was evaluated for susceptibility testing of second-line drugs including 
levofloxacin, amikacin, capreomycin and ethionamide with overall agreement of 96% at 
critical concentrations when compared to the agar proportion method (Lin et al., 2009). 
Similar results were obtained in a study comparing the manual version of the MGIT to the 
agar method using the second-line drugs ofloxacin, kanamycin, ethionamide, and 
capreomycin (Martin et al., 2008). In both studies, the agreement between the two methods 
for ethionamide was markedly lower (86-88%) than for the other drugs (Martin et al., 2008; 
Lin et al., 2009).  
Another fully automated broth system that is FDA-approved for susceptibility testing of 
Mtb complex is the VersaTREK instrument (TREK Diagnostics, Cleveland, OH). The 
VersaTREK (formerly ESP culture system II) is FDA-approved for susceptibility testing of 
Mtb complex against the first-line drugs including RIF (1 µg/ml), INH (0.4 µg/ml and 0.1 
µg/ml), ETH (8 µg/ml and 5 µg/ml), and PZA (100 µg/ml) (CLSI, 2008). Drug susceptibility 
for each isolate tested is manually determined by comparing the time to detection of growth 
between the control bottle and the bottle containing the drug. If the difference is greater than 
three days or if the bottle remains negative, the isolate is considered susceptible. If the 
difference is less than or equal to 3 days, then the isolate is considered resistant. However, 
for the test to be valid, the time to growth in the control bottle has to be between 3 and 10 
days following inoculation with 0.5 mL of a 1:10 dilution of a 1.0 McFarland inoculum 
(Bergmann & Woods, 1998; Ruiz et al., 2000). Evaluation of the VersaTREK instrument 
against the agar proportion method or the BACTEC 460 for susceptibility testing of Mtb 
against INH, RIF, ETB, and STR showed results similar to the MGIT 960, with agreement > 
than 95% for all drugs except ETB and STR (agreement between 90-95%) for which the 
VersaTrek generally called susceptible organisms that were resistant (Bergmann & Woods, 
1998), although only a few isolates were tested in the study. Similar results were obtained by 
other investigators, except for STR, which unlike the previous study, had an agreement of 
99.7% with the BACTEC 460 method (Ruiz et al., 2000).  
7.3 Molecular detection of resistance markers 
Although conventional methods described above are still the main-stay in detection of drug 
resistance in most laboratories, several studies have been conducted to developed more 
rapid and specific methods of detection of multi-drug resistance markers in Mtb complex. 
These assays are based on the detection of specific mutations in a variety of genes reported 
to confer resistance to several of the anti-tuberculosis drugs.  
The Genotype MTBDRplus (Hain Lifescience) is a commercial line probe assay developed 
for the detection of INH and RIF resistance in Mtb complex isolates and smear-positive 
specimens (Hillemann et al., 2007). Resistance to INH results from mutations in genes whose 
products are involved in the activation and binding of INH including the katG, the inhA, the 
ahpC-oxyR, ahpC and ndh genes, while resistance to RIF is due mainly to mutation in the rpoB 
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gene, which encodes the ┚-subunit of the DNA-dependent RNA polymerase, RIF binding 
target (Zhang & Yew, 2009).  
The Genotype MTBDRplus assay detects the most common mutations found in the rpoB, 
katG and inhA genes, an improvement from other line-probe assays such as the INNO-LiPA 
Rif (Innogenetics) and the GenoType MTBDR (Hain Lifescience), which only target the rpoB 
mutation (INNO-LiPA Rif) or rpoB and katG mutations (GenoType MTBDR). Evaluation of 
the Genotype MTBDRplus assay by Hillemann et al (Hillemann et al., 2007) on clinical 
strains and smear-positive sputa revealed a detection rate of 98.7% (74/75) and 96.8% 
(30/31) of RIF resistance in clinical isolates and sputa specimens respectively. INH 
resistance was detected in 92% (69/75) and 90% (36/41) of clinical isolates and sputa 
specimens respectively. Similar detection rate were obtained by Barnard et al (Barnard et al., 
2008) who tested 536 consecutive smear-positive sputum specimens with a sensitivity of 
98.9% for detection of RIF resistance and 94.2% for the detection of INH resistance when 
compared to results obtained with conventional methods. Although the assay is limited to 
the detection of known mutations of RIF and INH, the high concordance rate with 
conventional methods and the rapid time to results makes the MTBDRplus assay a useful 
test for the management of multi-drug resistance tuberculosis.  
Another version of the line probe assay, the GenoType MTBDRsl (second-line) (Hain 
Lifescience), was recently introduced for the detection of mutations in the gyrA gene, the 16S 
rRNA gene and the embB gene which confer resistance to fluoroquinolones, 
aminoglycosides and capreomycin, and ethambutol respectively (Hillemann et al., 2009). 
This assay shows variable performance characteristics when compared to phenotypic 
methods or sequencing, ranging from 75.6-90% for fluoroquinolones, 43-100% for 
aminoglycosides, 71.4-87.5% for capreomycin and suboptimal rate in all studies for 
ethambutol (38.5-64.2%) (Hillemann et al., 2009; Kiet et al., 2010; Huang et al., 2011; 
Kontsevaya et al., 2011). 
Multiple home-brew PCR assays have been developed for the detection of the most common 
gene mutations conferring resistance to Mtb complex strains. A recent study reports the 
development of a multiplex real-time PCR assay to detect all known mutations in the gyrA 
gene responsible for conferring resistance to fluoroquinolones (Chakravorty et al., 2011). 
This assay is based on an asymmetrical PCR using sloppy molecular beacon probes that 
extends the entire quinolone resistance determining region (QRDR), a region of the gyrA 
gene containing most of the known mutations responsible for fluoroquinolones resistance 
(Takiff et al., 1994). This assay was 100% sensitive and 100% specific in detecting 
fluoroquinolones resistance in 92 clinical isolates of Mtb complex, when compared to 
sequencing.  
As many as 21 mutations in the katG gene can cause decreased activity of INH against Mtb 
complex (Ando et al., 2010). Although several assays have focused on the S315T mutation of 
KatG (Mokrousov et al., 2002; Zhang et al., 2007; Tho et al., 2011), which is known to confer 
high-level resistance to INH and be present in as many as 90% of resistant Mtb isolates in 
Russia (Marttila et al., 1998; Mokrousov et al., 2002), the study by Ando and colleagues 
showed that other mutations in the KatG gene can cause high-level resistance and those 
should be included in molecular assays targeting the katG gene (Ando et al., 2010).  
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The utility of the assays is limited since they often target detection of resistance to one class 
of antimicrobial, depends on the available knowledge of current mutations conferring 
resistance, and as such, can only be use in conjunction with other assays. Several 
investigators have focused their efforts in developing assays similar to the MTBDRplus 
assay to include resistant marker to more than one class of antituberculosis drugs and for 
more than one mutation per gene target (Sekiguchi et al., 2007; Zhang et al., 2007; Ong et al., 
2010; Pholwat et al., 2011).  
Other molecular assays that have been developed for the detection of resistance markers 
have included locked nucleic acid probes (van Doorn et al., 2008) and multiplex PCR 
amplimer conformation analysis (Cheng et al., 2004), pyrosequencing (Marttila et al., 2009; 
Garza-Gonzalez et al., 2010; Halse et al., 2010), oligonucleotide microarray (Caoili et al., 
2006), and mass spectrometry (Wang et al., 2011). 
8. Future directions 
Clinical diagnostics for Mtb continue to evolve (Wilson, 2011) and in some cases, the future 
may be at our fingertips (Van Rie et al., 2010). For example, the GeneXpert MTB/RIF PCR 
assay (Cepheid, Sunnyvale, CA) allows for the automated, direct detection of Mtb complex 
in respiratory specimens and it has been endorsed by the WHO for use in low-income 
countries (WHO, 2008). The Xpert assay provides excellent sensitivity and specificity from 
direct specimens while providing a same day turn-around time for results (Helb et al., 2010; 
Boehme et al., 2011; Marlowe et al., 2011; Rachow et al., 2011; Scott et al., 2011). In addition, 
the assay provides immediate information on RIF resistance and has recently been 
successfully evaluated using non-respiratory specimens (Ioannidis et al., 2011; Miller et al., 
2011).  
Older technologies utilized in new ways are also making inroads in Mtb diagnostics. The 
use of mass spectrometry for the identification of Mtb complex from culture isolates may 
replace current standards such as biochemical analysis, nucleic acid hybridization probes, 
and DNA sequencing due to the ability of mass spectrometry to rapidly and accurately 
identify Mtb in a cost-effective manner while minimizing technologist hands-on time and 
effort (Saleeb et al., 2011). Although still in it's infancy in the diagnostic microbiology 
laboratory, this technology may also have utility in predicting drug resistance patterns and 
evaluating epidemiologic groups (Bouakaze et al., 2011; Massire et al., 2011; Schurch et al., 
2011). 
Finally, new technologies such as next generation sequencing are still largely utilized for 
research purposes in microbiology but some authors have suggested that there may come a 
time when application of this powerful technology will find a niche in the diagnostic 
microbiology laboratory (Ansorge, 2009; Rogers & Bruce, 2010; Engelthaler et al., 2011; 
Pallen & Loman, 2011). 
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